COSMAX announced on the 20th that it received a commendation from the Minister of Trade, Industry and Energy during the 61st Inventor's Day ceremony. This recognition underscores the company's efforts in establishing a virtuous cycle of technology, scholarship, and industrialization in the field of skin microbiome research.

In 2019, COSMAX successfully commercialized the world's first skin microbiome cosmetics utilizing skin microorganisms, particularly the discovery of a novel microorganism, EPI-7, which is prevalent in young, healthy skin. This breakthrough positions COSMAX as a leader in innovative skincare solutions by not only discovering the microorganism but also delineating its mechanism of action.

Moreover, COSMAX has redefined microbiomes as core technological elements in cosmetic formulations rather than simply efficacy components. This transition offers a strategic pathway to transform the chemical-centric cosmetics industry into a bio-based, high-value industry, presenting opportunities for new revenue streams through advanced technology.

To date, the company has systematically accumulated its technology achievements through research papers and patents, boasting 19 published papers and filing 124 patents, with 67 registered. COSMAX has successfully secured technology protections in key markets such as the United States, China, and Hong Kong, thereby enhancing its competitive edge in the global market.

Collaboration with prominent domestic universities, hospitals, and research institutions has not only elevated the sophistication of its technologies but also reduced dependency on foreign technologies, solidifying COSMAX’s position as a unique asset in K-beauty’s international market presence. Currently, the company is extending its microbiome research to consumers in major regions like the U.S. and China, thereby expanding its market reach and validating its technological prowess.

The accumulated academic expertise and intellectual property have translated into tangible business results, with skin microbiome technologies being seamlessly integrated into products recognized in markets including the U.S., Europe, and China. Particularly notable is the ongoing joint research aimed at developing eco-friendly nano-emulsion technology in collaboration with a leading global cosmetics company.

In recognition of its achievements, COSMAX is expected to receive multiple awards, including the 2024 Korea Technology Award. The research on skin microbiomes is evolving into a platform that integrates microbiome, genomic, and cellular data through an AI-driven skin diagnostic platform called FaceLink and a machine learning algorithm named Skimynet. This strategic direction indicates a substantial shift toward data-driven digital healthcare within the cosmetics industry.

According to Sang-Hyun Kang, head of the COSMAX R&I unit, "This award represents the culmination of over 15 years of focus on skin microbiome research by the COSMAX Group. Our strengths in connecting foundational technology and product development will enable K-beauty bio-technology to sustain its competitive edge in the global market."